Our leadership combines deep oncology expertise with a proven track record of delivering drugs to market.
Read more about who we are.
Ana has +20 years of experience in oncology research from both academia and industry. She received Ph.D. in cellular biology and health economics education from the Medical Faculty, University of Oslo. She conducted her academic research on solid tumor therapies at the Department of Pathology, Oslo University Hospital, and The Wistar Institute, Philadelphia US.
She was translational research director at Oncopeptides AB where she was responsible for developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Before joining Oncopeptides AB, she was also the principal investigator for in vivo pharmacology at Medivir AS.
Thomas has +20 years experience as professor, researching DNA damage response (DDR) and DNA repair at University of Oxford, Univ of Sheffield, Stockholm University and now Karolinska Institutet. He currently heads a large multidisciplinary translational research group at SciLifeLab, Helleday Laboratory, focusing on understanding DDR biology and translating the findings into novel anti-cancer treatments concepts and drugs. The group was first to demonstrate the synthetic lethality concept for treating cancer by showing homologous recombination defective cancers (e.g., BRCA) were sensitive to PARP inhibitors. Professor Helleday has been awarded numerous eminent international grants and awards in recognition of his research accomplishments including the Eppendorf-Nature Young European Investigator Award, ERC advanced grants and Anders Jahre’s Award for Medical Research.
Eva is a MD, PhD and board-certified oncologist, with over 20 years of leadership in global clinical oncology development. Former CMO at IO Biotech; Executive Director at Boehringer Ingelheim; and Medical Director, Oncology at Genmab and Novo Nordisk. Eva has led the development of multiple programmes through to FDA and EMA approval and has successfully supported multiple fundraising rounds at clinical-stage biotech companies.
Victoria has + 20 years of experience in clinical operations and drug development from biotechs, CRO and the pharma industry previously holding positions at Cinclus, Mendus, Oncopeptides, PPD and AstraZeneca.
Antoine is a MD and certified Pediatrician from the University of Paris-Sud 11 and also holds a Master’s degree in Immunology from the University of Paris. Previous appointments include Senior Director, Oncology and Global Clinical Development at the Aventis Group, Senior Director of Oncology at Johnson & Johnson and executive Director of Oncology at Schering-Plough. He was head of global oncology development at AstraZeneca, delivering TAGRISSO and LYNPARZA. Here he also served as Senior Vice President, GMD Head of Oncology and Lead, China GMD. He was Executive Vice President, Global Head of Oncology Research and Development at Daiichi Sankyo responsible for developing ENHERTU.
See bio under Management
Dr. Larsson trained at the Karolinska Institute (KI), Harvard Medical School and the MRC Human Genetics Unit in Edinburgh, and is an Associate Professor at KI. He spent 25 years with the Stockholm office of The Boston Consulting Group (BCG), where he founded and first led BCG’s global Payer and Provider sector and its Health Systems sector, and led BCG’s work on value-based health care. He is co-founder and Board Chair of the International Consortium for Health Outcomes Measurement (ICHOM), and a Distinguished Fellow with the World Economic Forum’s Health and Healthcare group. His book The Patient Priority was published by McGraw Hill in November 2022. Dr. Larsson has authored more than 30 peer-reviewed scientific publications and serves as a board member of Industrifonden, Symcel AB and Caneon AB.
Dr. Shah is Partner and Head of Healthcare at Nordic Capital Advisors, a position he has held since 2015, and brings over 30 years of experience across the healthcare industry. He holds several non-executive positions and serves on the board of several of Nordic Capital’s most significant portfolio investments. His healthcare experience spans both clinical practice — having initially qualified and practised as a cardiac surgeon at Oxford — and extensive transactional experience gained as Co-Head of Goldman Sachs’ healthcare investment banking practice, where he advised private equity and corporate clients.
Professor of Experimental Cancer Medicine, Newcastle University Centre for Cancer, UK
MD, Professor of Medicine Emeritus
Co-Director, Center for Experimental Therapeutics in Cancer and Senior Advisor to the Director UC Davis Comprehensive Cancer Center, Sacramento, US
Tim Yap, MD, PhD is a Medical Oncology Physician-Scientist and a Tenure-Track Associate Professor in the Departments of Investigational Cancer Therapeutics (Phase I Program), and Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center (MDACC). He is also the Medical Director of the Institute for Applied Cancer Science, and Associate Director of Translational Research in the Institute for Personalized Cancer Therapy at MDACC which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.
Professor Johann de Bono is Regius Professor of Cancer Research at The Institute of Cancer Research and honorary consultant in medical oncology at The Royal Marsden Hospital. He led on the development of abiraterone, cabazitaxel, enzalutamide, olaparib, lutetium PSMA and the molecular genomic stratification and germline sequencing of advanced prostate cancer. Professor de Bono leads the Drug Development Unit at the Royal Marsden which comprises >100 staff and conducts >50 Phase I clinical trials at any one time and runs a research laboratory. He has been involved in developing more than 200 new agents and is currently evaluating many new drugs in early clinical trials. He has published >600 papers and has mentored many PhD students.
Sarah is a Professor of Medical Oncology in the University of Sheffield and Honorary Consultant in Medical Oncology at Weston Park Cancer Centre, Sheffield. Professor Danson qualified in 1996 from the University of Nottingham and was a Specialist Registrar and Cancer Research UK Clinical Research Fellow in Pharmacology at the Christie Hospital, Manchester before moving to Sheffield in November 2006. Since 2019 she is chair of the Adult ECMC Network in the UK and NIHR National Specialty Lead for Cancer: Early Phase.
Solna, Sweden, May 29th, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies that exploit cancer’s oncogene addition, today announced that a
Solna, Sweden, May 21, 2026. One-carbon Therapeutics AB, a clinical-stage biotechnology company pioneering first-in-class cancer therapies, today announced the appointment of Stefan Larsson, MD, PhD,